- Open
- 60.50
- High
- 62.75
- Low
- 59.00
- Close
- 60.10
- Change
- -1.50 (-2.48%)
- Volume
- 2,037,005
| 19 Nov 2026 | 07:00:07 | AVA6207 Overcomes TOP1i Resistance |
| 19 Nov 2026 | 07:00:00 | AVA6207 Overcomes Topoisomerase I Inhibitor Resistance In Vitro and In Vivo with Robust and Tumor-Selective Release of Dual Exatecan and ATR Inhibitor Payloads |
| 4 Nov 2026 | 07:00:09 | To Present pre|CISION® Dual Payload Candidate |
| 2 Nov 2026 | 07:00:11 |
| 22 Jun 2026 | Annual Report and Accounts (to 2025-12-31) | |
| 7 Jul 2025 | Annual Report and Accounts (to 2024-12-31) | |
| 6 Jul 2024 | Annual Report and Accounts (to 2023-12-31) |
Avacta Group plc develops novel cancer therapies and advanced diagnostic tools, focusing primarily on oncology therapeutics. The company utilizes its proprietary platforms, Affimer® and pre|CISION™, to create targeted peptide and antibody drug conjugates aimed at improving treatment outcomes while minimizing toxicity. Avacta is transitioning to a pure-play oncology company by divesting its diagnostics division, concentrating on the development of its therapeutic candidates, including AVA6000, AVA6103, and AVA7100, which target solid tumors. The company operates primarily in the biotechnology sector, serving patients with cancer and collaborating with partners in the healthcare industry.
| 19 Nov 2026 | 07:00:07 | AVA6207 Overcomes TOP1i Resistance |
| 19 Nov 2026 | 07:00:00 | AVA6207 Overcomes Topoisomerase I Inhibitor Resistance In Vitro and In Vivo with Robust and Tumor-Selective Release of Dual Exatecan and ATR Inhibitor Payloads |
| 4 Nov 2026 | 07:00:09 | To Present pre|CISION® Dual Payload Candidate |
| 2 Nov 2026 | 07:00:11 |
| 22 Jun 2026 | Annual Report and Accounts (to 2025-12-31) | |
| 7 Jul 2025 | Annual Report and Accounts (to 2024-12-31) | |
| 6 Jul 2024 | Annual Report and Accounts (to 2023-12-31) |
Avacta Group plc develops novel cancer therapies and advanced diagnostic tools, focusing primarily on oncology therapeutics. The company utilizes its proprietary platforms, Affimer® and pre|CISION™, to create targeted peptide and antibody drug conjugates aimed at improving treatment outcomes while minimizing toxicity. Avacta is transitioning to a pure-play oncology company by divesting its diagnostics division, concentrating on the development of its therapeutic candidates, including AVA6000, AVA6103, and AVA7100, which target solid tumors. The company operates primarily in the biotechnology sector, serving patients with cancer and collaborating with partners in the healthcare industry.
| 26 Oct 2026 | 13:00:00 | Faridoxorubicin Treatment Results in Near Doubling of Progression-Free Survival and Clinically Meaningful Tumor Shrinkage in Most Patients with Salivary Gland Cancers |
| 26 Oct 2026 |
| Faridoxorubicin PFS data in SGC at ESMO 2026 |
| 23 Oct 2026 | pre|CISION platform data and ongoing FOCUS-01 trial design with FAP-Exd (AVA6103) |
| 6 Oct 2026 | Restoration of trading on AIM |
| 6 Oct 2026 | Results of placing and subscription |
| 30 Sept 2026 | Capital access window |
| 30 Sept 2026 | Interim H126 results |
Lord Fink has interests in this issuer
| 26 Oct 2026 | 13:00:00 | Faridoxorubicin Treatment Results in Near Doubling of Progression-Free Survival and Clinically Meaningful Tumor Shrinkage in Most Patients with Salivary Gland Cancers |
| 26 Oct 2026 |
| Faridoxorubicin PFS data in SGC at ESMO 2026 |
| 23 Oct 2026 | pre|CISION platform data and ongoing FOCUS-01 trial design with FAP-Exd (AVA6103) |
| 6 Oct 2026 | Restoration of trading on AIM |
| 6 Oct 2026 | Results of placing and subscription |
| 30 Sept 2026 | Capital access window |
| 30 Sept 2026 | Interim H126 results |
Lord Fink has interests in this issuer
| Issuer | Mkt cap | 1Y |
|---|---|---|
AVCTAvacta Group plc | £294m | -0.2% |
| £280m | -0.1% | |
| £98m | -0.2% | |
| £32m | -0.2% | |
| £10m | -0.1% | |
| £4m | -0.2% |
| Issuer | Mkt cap | 1Y |
|---|---|---|
AVCTAvacta Group plc | £294m | -0.2% |
| £280m | -0.1% | |
| £98m | -0.2% | |
| £32m | -0.2% | |
| £10m | -0.1% | |
| £4m | -0.2% |